Key Points – Sanofi raised its 2026 outlook after second-quarter sales rose 17.8% to €11.6 billion and business EPS increased 33.3%, driven by Dupixent, new medicines and cost discipline. – Dupixent quarterly sales surpassed €5 billion, up 37%, prompting Sanofi to lift its 2030…
les ambition for the drug to approximately €25 billion. Launch products and rare-disease medicines also delivered strong growth, while vaccines declined 5% year over year. – Sanofi’s pipeline review led to multiple program discontinuations or strategic changes, including amlitelimab, itepekimab and balinatunfib, as the company seeks greater development rigor and plans to increase disciplined business-development and M&A activity. – Giants Costco, Sanofi, and SAP Raise Dividends by Over 10% Sanofi (NASDAQ:SNY) raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline
The company also increased its 2030 sales ambition for Dupixent to approximately €25 billion while outlining an ongoing review of its research pipeline and broader growth strategy. Second-quarter net sales increased 17.8% at constant exchange rates to €11.6 billion, Chief Financial Officer François said. Sales growth was primarily volume-driven, though results also included “a couple of hundred millions” of positive gross-to-net adjustments.
Restating prior-year figures for Dynavax and Blueprint sales, growth would have been about 15%, he said. – Analysts Can’t Get Enough of These Little-Known Biopharma Stocks Business operating income rose 35.8%, with margin expanding 3.8 percentage points. François said underlying business operating income growth was around 20% after excluding favorable items, including approximately €80 million more in capital gains than the prior-year quarter. Business EPS rose 33.3%, or 21% excluding share repurchases and one-off items.